Augmentation strategies are commonly applied when an individual is unresponsive to antidepressant monotherapy. Lamotrigine is currently considered at best only as second line augmentation for treatment-resistant unipolar depression while its clinical efficacy and safety profiles remain inconclusive. We intended to assess the therapeutic effects and safety profiles of lamotrigine augmentation in patients with treatment-resistant unipolar depression by conducting a meta-analysis.
Methods:
MEDLINE, Embase, EBSCO, Cochrane, Web of Science, Scopus, Wanfang and Ariniti databases were searched. Coprimary outcomes, including changes in severity of depression and response rate, were measured in this study. Secondary outcomes were defined as the safety profile of the intervention, including reported discontinuation rate and adverse events.
Results:
Eight double-blinded randomized controlled trials with 677 patients overall were included. Significant improvements in Hamilton Rating Scale for Depression scores and response rates were shown in lamotrigine augmentation groups compared with control groups, of which the pooled result of six Chinese studies showed positive effects of Hamilton Rating Scale for Depression improvement while the pooled result of two non-Chinese studies was statistically non-significant. Patients with more severe illness and longer duration of illness were more effectively treated with lamotrigine augmentation. The magnitude of depression improvement after lamotrigine augmentation was higher in patients treated with selective serotonin reuptake inhibitors than those treated with serotonin-norepinephrine reuptake inhibitors. Lamotrigine augmentation is well-tolerated in terms of all-cause discontinuation rate and adverse events.
Conclusions:
Lamotrigine augmentation may serve as a possible choice for patients with treatment-resistant unipolar depression and further trials are warranted to clarify the optimal dosage of lamotrigine augmentation together with the treatment duration and safety over time.
AmannBBornCCrespoJet al. (2011) Lamotrigine: When and where does it act in affective disorders? A systematic review. J Psychopharmacol25: 1289–1294.
3.
AngstJMerikangasKRCuiLet al. (2018) Bipolar spectrum in major depressive disorders. Eur Arch Psychiatry Clin Neurosci268: 741–748.
4.
BalestriMCalatiRSoueryDet al. (2016) Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. J Affect Disord189: 224–232.
5.
BarbeeJGJamhourNJ (2002) Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry63: 737–741.
6.
BarbeeJGThompsonTRJamhourNJet al. (2011) A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry72: 1405–1412.
7.
ChangC-MSatoSHanC (2013) Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression. CNS Drugs27: 21–27.
8.
ChenYF (2002) Chinese classification of mental disorders (CCMD-3): Towards integration in international classification. Psychopathology35: 171–175.
9.
EggerMZellweger-ZähnerTSchneiderMet al. (1997) Language bias in randomised controlled trials published in English and German. Lancet350: 326–329.
10.
FavaM (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry53: 649–659.
11.
FournierJCDeRubeisRJHollonSDet al. (2010) Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA303: 47–53.
12.
FriedrichMJ (2017) Depression is the leading cause of disability around the world. JAMA317: 1517–1517.
13.
GabrielA (2006) Lamotrigine adjunctive treatment in resistant unipolar depression: An open, descriptive study. Depress Anxiety23: 485–488.
14.
GutierrezRLMcKercherRGaleaJet al. (2005) Lamotrigine augmentation strategy for patients with treatment-resistant depression. CNS Spectr10: 800–805.
15.
GuyattGHOxmanADVistGEet al. (2008) GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ336: 924–926.
16.
HawleyCJGaleTMSmithVRet al. (1998) Depression rating scales can be related to each other by simple equations. Int J Psychiatry Clin Pract2: 215–219.
17.
HigginsJPAltmanDGGotzschePCet al. (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ343: d5928.
18.
HigginsJPTGreenS (eds) (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. London: The Cochrane Collaboration.
19.
HirschfeldRM (2014) Differential diagnosis of bipolar disorder and major depressive disorder. J Affect Disord169: S12–S16.
20.
IdrisNZN (2012) A comparison of methods to detect publication bias for meta-analysis of continuous data. J Appl Sci12: 1413–1417.
21.
IvkovićMDamjanovićAJovanovićAet al. (2009) Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: Efficacy and tolerability. Psychiatr Danub21: 187–193.
22.
KagawaSMiharaKNakamuraAet al. (2014) Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder. Ther Drug Monit36: 730–733.
23.
KhanALeventhalRMKhanSRet al. (2002) Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database. J Clin Psychopharmacol22: 40–45.
24.
KaufmanKGernerR (1998) Lamotrigine toxicity secondary to sertraline. Seizure7: 163–165.
25.
LapidusKASoleimaniLMurroughJW (2013) Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat9: 1101–1112
26.
LiCChuiGSongZ (2009) Clinical observation of lamotrigine augmenation with sertraline on the geriatric treatment-resistant depression. Chin J Gerontol29: 96–97 [in Chinese].
27.
LiQHuCMaH (2015) A control study of lamotrigine combined with paroxetine for the treatment of refractory depression. J Psychiatry (China)28: 284–286 [in Chinese].
28.
LuoQYeHLiuYet al. (2016) Clinical study on curative effect of paroxetine combined with lamotrigine or valproate on refractory depression. China Licensed Pharmacist13: 7–12 [in Chinese].
29.
MaSWangXMuXet al. (2016) Efficacy observation of sertraline combined with quetiapine and lamotrigine in treatment of refractory depression. Med J Chin People’s Health28: 4–6 [in Chinese].
30.
MalhiGSDasPMannieZet al. (2019) Treatment-resistant depression: Problematic illness or a problem in our approach?Brit J Psychiatry214: 1–3.
31.
McIntyreRSFilteauM-JMartinLet al. (2014) Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach. J Affect Disord156: 1–7.
32.
MiharaKNakamuraANemotoKet al. (2016) Lamotrigine augmentation therapy in a case with treatment-resistant unipolar depression that showed insufficient response to electroconvulsive therapy. Psychiatry Clin Neurosci70: 126.
33.
MilosheskaDLorberBVovkTet al. (2016) Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. Br J Clin Pharmacol82: 399–411.
34.
MoherDLiberatiATetzlaffJet al. (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol62: 1006–1012.
35.
MusazziLTreccaniGMalleiAet al. (2013) The action of antidepressants on the glutamate system: Regulation of glutamate release and glutamate receptors. Biol Psychiatry73: 1180–1188.
36.
NaughtonMClarkeGOliviaFOet al. (2014) A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord156: 24–35.
37.
NelsonJCBaumannPDelucchiKet al. (2014) A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord168: 269–275.
38.
ObachRSCoxLMTremaineLM (2005) Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study. Drug Metab Dispos33: 262–270.
39.
OstadhadiSAhangariMNikouiVet al. (2016) Pharmacological evidence for the involvement of the NMDA receptor and nitric oxide pathway in the antidepressant-like effect of lamotrigine in the mouse forced swimming test. Biomed Pharmacother82: 713–721.
40.
PapadimitropoulouKVossenCKarabisAet al. (2017) Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: A systematic review and network meta-analysis. Curr Med Res Opin33: 701–711.
41.
ParkY-MLeeB-H (2016) Treatment response in relation to subthreshold bipolarity in patients with major depressive disorder receiving antidepressant monotherapy: A post hoc data analysis (KOMDD study). Neuropsychiatr Dis Treat12: 1221–1227.
42.
PriceRBShunguDCMaoXet al. (2009) Amino acid neurotransmitters assessed by 1H MRS: Relationship to treatment-resistance in major depressive disorder. Biol Psychiatry65: 792–800.
43.
RabinowitzJWerbeloffNMandelFSet al. (2016) Initial depression severity and response to antidepressants v. placebo: Patient-level data analysis from 34 randomised controlled trials. Br J Psychiatry209: 427–428.
44.
RuhéHGvan RooijenGSpijkerJet al. (2012) Staging methods for treatment resistant depression. A systematic review. J Affect Disord137: 35–45.
45.
SantosMARochaFLHaraC (2008) Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: A randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry10: 187–190.
46.
SchindlerFAnghelescuIG (2007) Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: A randomized, open-label study. Int Clin Psychopharmacol22: 179–182.
47.
SharmaVKhanMSmithA (2005) A closer look at treatment resistant depression: Is it due to a bipolar diathesis?J Affect Disord84: 251–257.
48.
SolmiMVeroneseNZaninottoLet al. (2016) Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: A comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectr21: 403–418.
SpielmansGIBermanMILinardatosEet al. (2013) Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes. PLoS Med10: e1001403.
51.
TakeshimaNSozuTTajikaAet al. (2014) Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?BMC Med Res Methodol14: 30.
52.
TaylorDPatonCKapurS (2015) The Maudsley Prescribing Guidelines. 12th ed.London: Wiley-Blackwell.
53.
ThomasSPNandhraHSJayaramanA (2010) Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD). J Ment Health19: 168–175.
54.
TianXSongGM (2015) China’s medical research integrity. Lancet386: e17.
55.
TrivediMHRushAJWisniewskiSRet al. (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry163: 28–40.
56.
TurnerEHMatthewsAMLinardatosEet al. (2008) Publication of antidepressant trials and its influence on apparent efficacy.N Engl J Med358: 252–260.
57.
Van RandenborghAHüffmeierJVictorDet al. (2012) Contrasting chronic with episodic depression: An analysis of distorted socio-emotional information processing in chronic depression. J Affect Disord141: 177–184.
58.
WangL (2012) Clinical study of lamotrigine amalgamation of venlafaxine on the treatment-resistant depression. Tianjin Pharmacy24: 9–11 [in Chinese].
59.
WHO (1992) The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization.
60.
WHO (2017) Depression and other common mental disorders: Global health estimates. In Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization.
61.
YangCHYangHZGaoXet al. (2016) Comparative study of lamotrigine combined with escitalopram in the treatment of MECT-resistant patients with depressive disorder. Sichuan Ment Health29: 406–409 [in Chinese].
62.
ZavodnickADAliR (2012) Lamotrigine in the treatment of unipolar depression with and without comorbidities: A literature review. Psychiatr Quart83: 371–383.
63.
ZhangFTianB (2016) A comparative study of duloxetine combined with lamotrigine in the treatment of patients with treatment-resistant depression. J Psychiatry (China)29: 335–338 [in Chinese].
64.
ZhouXRavindranAVQinBet al. (2015) Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: Systematic review and network meta-analysis. J Clin Psychiatry76: e487–e498.
65.
ZimmermanMMartinezJHYoungDet al. (2013) Severity classification on the Hamilton depression rating scale. J Affect Disord150: 384–388.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
